COMPANY

AllRock Bio

Company-reported stage: Phase 1 · source · Oct 12, 2026

Keywords: respiratory pulmonary hypertension Pulmonary Arterial Hypertension ROC-101

Location: Natick, MA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series A · $50M · announced Sep 16, 2025 Company release ↗
Source quote
- Sep 16, 2025 · Company release ↗
  “AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in PAH and ILD-PH patients Topline data from ROC-101 Phase 1 study demonstrate favorable safety and tolerability, and”

Raises announced in these releases: $50M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Oct 1, 2025 Trial start Phase 2: A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) source ↗
Sep 16, 2025 Raise Private equity round — Series A: $50M (total, as published), announced Sep 16, 2025. Source: company's own press page. source ↗
Sep 16, 2025 Raise Series A · $50M source ↗

2027-03 (ESTIMATED) · Phase 2 · A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) · NCT07175038

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $50.0M. Last 2 years.

Sep 16, 2025 Private equity round — Series A: $50M (total, as published), announced Sep 16, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07175038	A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)	Phase 2	Recruiting	Oct 1, 2025	2027-03 (estimated)